Liver Diseases  >>  uprifosbuvir (IDX21437)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
uprifosbuvir (IDX21437) / Merck (MSD)
NCT01974687 / 2013-004043-23: Single and Multiple Dose Study of Uprifosbuvir (MK-3682/IDX21437) in Healthy and Hepatitis C Virus (HCV)-Infected Participants (MK-3682-001)

Completed
1/2
178
NA
Uprifosbuvir, MK-3682/IDX21437, Placebo, Itraconazole, Sporanox®
Merck Sharp & Dohme LLC
Chronic Hepatitis C
09/15
09/15

Download Options